Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Please join us for an ECHO (Entrepreneurship for Cardiovascular Health Opportunities) seminar featuring Dr. Jennifer Moody (Chief Operating Officer, Morphocell Technologies) on Tuesday January 28, 2020 (11 am – 12 pm) in the TBEP lounge (MaRS West Tower, 661 University Ave, 14th floor).
Dr. Moody’s presentation entitled, “Engineering Liver Function: Using Stem Cells to Improve How we Treat Liver Failure”, will feature an overview of Morphocell Technologies, its technologies and the story behind its success. Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.
Light refreshments will be served.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).